Sanofi Stock News

French drugmaker Sanofi on Thursday reaffirmed its ambition to deliver more than 10 billion euros ($10.89 billion)in annual vaccines sales by 2030, driven by core franchises of influenza, meningitis,

Sanofi said that trials show the currently available mRNA technology behind the most successful COVID-19 shots will not be effective against influenza and it is already working on a next generation of

Sanofi's (SNY) phase II study, investigating amlitelimab for moderate-to-severe atopic dermatitis in adults, meets the primary endpoint.

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Sanofi (SNY) have what it takes?

Markets eased lower in premarket trading to open the week Tuesday morning. Dice Therapeutics received an acquisition bid from Eli Lilly.

These European pharma giants have long-established records of success. AstraZeneca has 12 medicines that are on track to become blockbusters.

The U.S. Food and Drug Administration advisers on Thursday backed the use of Sanofi and partner AstraZeneca's experimental antibody to prevent respiratory syncytial virus (RSV) infections in infants.

Advisers to the U.S. Food and Drug Administration voted unanimously Thursday to recommend a monoclonal antibody developed by Sanofi SNY, +1.30% and AstraZeneca AZN, +1.28% to protect infants from resp

Our 3-step process focuses on wide-moat stocks (as per Morningstar's rating). We are only interested in those targets that are attractively valued. We share the heat map of the most investable candida

The approval of GSK's RSV vaccine for older adults is based on positive data from the pivotal AReSVi-006 phase III study.

The U.S. Food and Drug Administration's staff reviewers on Tuesday raised no new concerns on Sanofi and partner AstraZeneca's experimental therapy to prevent respiratory syncytial virus (RSV) infectio

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Sanofi (SNY) have what it takes?

Sanofi's (SNY) phase II study on its novel investigational anti-CD40L antibody, frexalimab, meets the primary endpoint.

French healthcare company Sanofi announced on Wednesday positive data for its frexalimab product aimed at treating multiple sclerosis, and that the firm plans to initiate pivotal trials in multiple sc

Sanofi's wide lineup of medicines across several therapeutic areas makes it attractive. Axsome Therapeutics is rising in prominence thanks to an exciting pipeline.